Introduction
============

Angiosarcoma (AS), a highly malignant and rare tumor of vascular or lymphatic endothelial cell origin with a poor prognosis ([@b1-mco-0-0-02119]), arises in the scalp and face in the elderly, in association with chronic lymphedema, and in irradiated areas ([@b1-mco-0-0-02119],[@b2-mco-0-0-02119]). AS associated with chronic lymphedema is known as Stewart-Treves syndrome (STS) ([@b2-mco-0-0-02119]). STS is primarily described in patients with lymphedema of an upper extremity occurring after breast cancer surgery including radical axially lymph node dissection and subsequent radiation therapy (RT). STS accounts for approximately 5% of AS ([@b3-mco-0-0-02119]), and is rarely described in the presence of chronic lymphedema of the lower abdominal wall.

Eribulin mesylate (eribulin) is a structurally modified analog of halichondrin B, originally isolated from the marine sponge *Halichondria okadai*. Its mode of action is distinct from other tubulin inhibitors and involves binding to specific sites on the growing positive ends of microtubules to inhibit their growth ([@b4-mco-0-0-02119]). Eribulin was approved in Japan for the treatment of patients with soft tissue sarcoma in 2016. The efficacy of eribulin for AS has not been evaluated sufficiently till date.

Herein, we report a rare case of STS in the lower abdominal wall successfully treated with eribulin.

Case report
===========

The patient, a 76-year-old woman, underwent a radical hysterectomy with bilateral salpingo-ophorectomy and pelvic lymphadenectomy for cervical cancer 12 years earlier. Postoperative RT of 50.4 Gy in 28 fractions was administered. After treatment, lymphedema progressed in her lower abdominal wall and bilateral legs and she was treated with antibiotics for cellulitis repeatedly. Then, she noticed a mass on her left lower abdominal wall, where chronic lymphedema had developed. The mass grew rapidly for 3 months and she was referred to our outpatient clinic.

Magnetic resonance imaging (MRI) demonstrated that the mass was heterogenous isointense on T1-weighted image and heterogenous hyperintense on T2 weighted image ([Fig. 1A](#f1-mco-0-0-02119){ref-type="fig"}). Diffuse thickening of cutis and subcutis as well as edema of subcutaneous tissues could be seen in the abdomen, groin, buttocks, and legs. Multiple enhancing nodules in the left lower abdominal wall and edema of subcutaneous tissues were revealed by contrast-enhanced computed tomography (CT) scan of the abdomen ([Fig. 1B](#f1-mco-0-0-02119){ref-type="fig"}). On fluorodeoxyglucose positron emission tomography (FDG-PET)/CT scan, hypermetabolism (maximum standardized uptake values=22.0) was observed in the mass of the left lower abdominal wall ([Fig. 1C](#f1-mco-0-0-02119){ref-type="fig"}), but distant metastasis was not detected. Immunohistologic examination of needle biopsy specimens of AS tested positive for CD31, D2-40, and ERG ([Fig. 2A-D](#f2-mco-0-0-02119){ref-type="fig"}). Based on the morphology, immunoprofile, and clinical presentation, the patient was diagnosed with STS.

We judged the tumor unresectable and the combination chemotherapy with gemcitabine (720 mg/m^2^) and docetaxel (80 mg/m^2^) was started. She demonstrated stable disease (SD) for 3 months. However, grade 4 neutropenia and anemia were observed. In addition, severe side effects such as fatigue, diarrhea, anorexia, vomiting, and weight loss occurred, and thus, the patient discontinued treatment after 3 cycles. Then, RT of 70 Gy in 35 fractions was carried out for the left lower abdominal wall tumor. The size of the mass decreased once but multiple reddish nodules, some of which were diagnosed as AS by excisional biopsies, developed in the whole abdominal wall 3 months after RT ([Fig. 3A](#f3-mco-0-0-02119){ref-type="fig"}). At this point, treatment with eribulin was initiated at a dose of 1.4 mg/m^2^. However, grade 3 and 4 neutropenia occurred on day 8 and 15, respectively. In addition, anorexia and diarrhea continued for 1 week after eribulin administration. Then, the dose was gradually reduced. Eribulin was dosed at 0.8 mg/m^2^ and was administered on day 1 of a 21-day cycle for 10 months. There was shrinkage of nodules in the lower abdominal wall after 4 courses of eribulin treatment, and no new lesions have developed. Treatment with eribulin is effective with tumor partial response (PR). MRI demonstrated that these effects lasted for 1 year without severe side effects ([Fig. 3B](#f3-mco-0-0-02119){ref-type="fig"}), and she still continues to receive eribulin treatment.

Discussion
==========

AS is a rare malignant tumor with a predilection for skin in the head and neck region, though it can appear anywhere on the body and has often been described as looking like a skin infection, a bruise, or a lesion ([@b1-mco-0-0-02119]). Its association with chronic lymphedema is well known ([@b1-mco-0-0-02119],[@b2-mco-0-0-02119]). STS was first described when Fred Stewart and Norman Treves reported a case series describing 6 patients with AS in the setting of chronic lymphedema that developed post radical mastectomy ([@b2-mco-0-0-02119]). Although it is widely accepted that lymphedema may induce AS, the mechanism remains unknown. Local immunodeficiency resulted from long-standing chronic lymphedema may be involved in oncogenesis of STS, and the development of AS has been associated with chronic lymphedema of any origin. STS typically occurs as a complication of long-lasting lymphedema of the arm after axillary lymph node dissection following a radical mastectomy and/or RT for breast cancer. STS can also appear in lower limbs with chronic lymphedema. However, STS has rarely been described in the presence of chronic lymphedema of the lower abdominal wall and postoperative cervical cancer. For women with cervical cancers, surgery that removes lymph nodes and/or RT to the pelvis may damage lymph nodes in that area and lymphedema often develops in the legs, abdomen, or groin area. Severe cellulitis infection may damage tissue around the lymph nodes or vessels and increase the risk of lymphedema. In this case, cellulitis occurred repeatedly in the lower abdomen, probably leading to lymphedema.

To date, more than 400 cases of STS have been reported in the English literature. Collectively, STS has very poor prognosis and is prone to local recurrence and distant metastasis ([@b1-mco-0-0-02119],[@b7-mco-0-0-02119],[@b8-mco-0-0-02119]). Because of the occurrence of metastatic spread and poor prognosis, proper diagnosis of AS is important. Due to the rarity of STS, there is no standardized therapy for this disease. Radical surgery by local resection with a negative margin is the only curable treatment available and complete tumor resection predicts improved prognosis ([@b9-mco-0-0-02119],[@b10-mco-0-0-02119]). Therefore, once the biopsy specimen has been diagnosed as STS, extensive resection, early amputation, or dissection of the joint and diseased limb are highly recommended, which may increase the survival rate of patients. However, in our case, we judged the tumor unresectable with a safety margin. The median survival is 2.5 years after diagnosis, with most patients dying from metastatic disease within 2 years ([@b1-mco-0-0-02119],[@b3-mco-0-0-02119],[@b7-mco-0-0-02119],[@b8-mco-0-0-02119]). The long-term survivorship is rare, and survival time of untreated patients is only 5-8 months post diagnosis.

AS is a highly aggressive and exceedingly rare soft tissue sarcoma. Despite a strong need for systemic therapies, the rarity of AS represents a major limitation to randomized trials and therefore very few prospective clinical studies focusing on the medical treatment are available. Standard chemotherapy for soft tissue sarcoma is based on anthracyclines as the first line treatment ([@b11-mco-0-0-02119]). Beside anthracyclines, taxanes can be active, both as single agents and in combination with gemcitabine in AS ([@b12-mco-0-0-02119]). Taxanes are the current first line treatment for patients with advanced AS who are considered difficult to treat with anthracyclines owing to advanced age or comorbidity. Anthracyclines can be difficult to administer in this patient due to high age and cardiac dysfunction. Tolerability of gemcitabine plus docetaxel is fair, with less cardiac toxicity compared with anthracyclines. Therefore, we administered combination therapy of gemcitabine and docetaxel in this patient.

Eribulin, a nontaxane microtubule-targeting agent, was originally approved for the treatment of breast cancer by the United States Food and Drug Administration in 2010. A phase III study comparing eribulin with dacarbazine in patients with advanced liposarcoma or leiomyosarcoma showed significant improvement in overall survival (OS) for the eribulin arm, with a manageable toxicity profile ([@b20-mco-0-0-02119],[@b21-mco-0-0-02119]). In the liposarcoma subgroup, OS was significantly improved with eribulin vs dacarbazine (15.6 vs. 8.4 months) and progression free survival was also improved with eribulin vs. dacarbazine (2.9 vs. 1.7 months) ([@b20-mco-0-0-02119],[@b21-mco-0-0-02119]). Based on the results of this phase III study, in 2016 eribulin was approved for the treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen in both the United States and Europe. On the other hand, exploratory analysis from a Japanese phase II study showed some efficacy of eribulin in patients with several subtypes of rare soft tissue sarcoma including synovial sarcoma, endometrial stromal sarcoma, solitary fibrous tumor, and fibrosarcoma ([@b22-mco-0-0-02119]). As a result, eribulin was approved for the treatment of all soft tissue sarcomas in Japan. However, little data exists regarding eribulin efficacy in rare histologic subtypes of soft tissue sarcomas such as AS.

Recently, 2 case reports from Japan described patients with AS whose disease was controlled successfully with eribulin mesylate ([@b23-mco-0-0-02119],[@b24-mco-0-0-02119]). Kobayashi *et al* demonstrated interim results of a post-marketing surveillance study of eribulin in soft tissue sarcomas including rare subtypes such as AS ([@b25-mco-0-0-02119]). In that study, of 12 AS patients, PR was achieved in 1 patient (8.3%) and SD was achieved in 2 patients (16.7%). However, treatment duration of eribulin in those 3 patients was less than 9 months. Fujisawa *et al* showed the promising efficacy of eribulin for treating patients with advanced cutaneous AS who previously received taxanes ([@b26-mco-0-0-02119]). The best overall response rate was 20%, and the median overall survival and progression-free survival were 8.6 and 3.0 months, respectively. It has been concluded that caution should be exercised regarding eribulin use in elderly patients. In the present case, PR was achieved and maintained for 1 year with eribulin. Since the dose of eribulin was low, we could continue eribulin treatment for the long time without severe side effects. Moreover, this is the first case in which eribulin demonstrated an excellent antitumor effect for STS, suggesting that eribulin should be one of the most promising options for the treatment of STS. Further studies are needed to confirm the benefit of eribulin for patients with AS and to establish predictive markers for eribulin sensitivity.
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![(A) MRI of the abdomen. Axial T1-weighted image showed that the mass was heterogenous iso-intensity signal and axial T2-weighted image showed that the mass was heterogenous high intensity signal. Diffuse thickening of the cutis and subcutis as well as edema of subcutaneous tissues were detected. Left, axial view on T1-weighted image; right, axial view on T2-weighted image. (B) Contrast-enhanced CT of the abdomen. Enhancing multiple nodules in the left lower abdominal wall and edema of the subcutaneous tissues were detected. (C) Fluorodeoxyglucose positron emission tomography/CT scan. Increased uptake corresponding to the mass in the left lower abdominal wall was seen (maximum standardized uptake values=22.0). MRI, magnetic resonance imaging; CT, computed tomography.](mco-13-05-02119-g00){#f1-mco-0-0-02119}

![Histopathology staining of the needle biopsy specimens. (A) Hematoxylin and eosin staining showed that the immature vascular structures are formed with atypical epithelioid and spindle cells; magnification, x100. (B) Immunohistological staining for CD31, (C) D2-40 and (D) ERG were positive; magnification, x100. CD31, cluster of differentiation.](mco-13-05-02119-g01){#f2-mco-0-0-02119}

![(A) MRI of the abdomen before eribulin administration. Multiple nodules (yellow arrows) were observed in the whole abdominal wall. (B) MRI of the abdomen 1 year after eribulin administration. Most nodules decreased in size. MRI, magnetic resonance imaging.](mco-13-05-02119-g02){#f3-mco-0-0-02119}
